Compare Matson Inc (MATX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Sana Biotechnology Inc — how do they compare? Matson Inc trades at $225.67 (market cap $6.81B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Matson Inc is far larger — about 8.1× Sana Biotechnology Inc's market cap, and Matson Inc pays a 0.67% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Sana Biotechnology Inc for 23 Days on average.
| MATX | SANA | |
|---|---|---|
Market Cap | $6.81B | $836.71M |
Volume | 255,080 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $238.60 | $5.92 |
52-Week Low | $88.05 | $2.68 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $7.41B | $749.96M |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $227.79, up 2.18% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 13.41% net income margin and 17.21% ROE, supported by positive analyst sentiment (66.7% buy ratings). Recent Q2 2026 earnings of $4.27 per share exceeded expectations by 12.7%, with the company raising full-year guidance amid resilient consumer demand and stable Trans-Pacific trade conditions.
Outlook remains positive with projected revenue growth to $3.5B in 2026 and improved cash flow. Key risks include freight market volatility and competitive pressures. Wall Street sees 27.3% upside potential based on average price targets, while institutional buying activity from Bank of America and Deutsche Bank signals confidence in the company's execution.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
